Autonomix Medical (NASDAQ:AMIX) Issues Earnings Results, Beats Expectations By $0.11 EPS

Autonomix Medical (NASDAQ:AMIX) posted its earnings results on Tuesday. The company reported ($2.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.62) by $0.11, FiscalAI reports.

Autonomix Medical Price Performance

Shares of AMIX traded down $0.11 during trading hours on Thursday, hitting $1.37. The stock had a trading volume of 244,186 shares, compared to its average volume of 1,691,313. The company’s fifty day moving average is $3.19 and its two-hundred day moving average is $6.47. Autonomix Medical has a 52 week low of $1.33 and a 52 week high of $32.55. The stock has a market capitalization of $1.33 million, a price-to-earnings ratio of -0.03 and a beta of -0.70.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Autonomix Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Autonomix Medical in a report on Monday, October 26th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $42.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc. is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures. Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.